Athira Pharma, Inc. (ATHA) - Dilution Analysis

10-Q filing | 9.4M shares outstanding

S-1/A filing: This prospectus relates to the disposition of up to 5,502,402 shares of common stock issuable upon the exercise of a pre-funded warrant by the selling stockholder.

10-K filing | 9.3M shares outstanding

S-1/A filing: This prospectus relates to the disposition of up to 58,464,567 shares of our common stock by selling stockholders.

S-3 filing: This prospectus relates to the disposition of up to 5,502,402 shares of common stock issuable upon the exercise of a pre-funded warrant by the selling stockholder.

S-3 filing: This S-3 filing from LeonaBio, Inc. relates to the disposition of up to 58,464,567 shares of common stock by selling stockholders.

8-K filing: Athira Pharma, Inc. enters into a private placement agreement to issue common stock, pre-funded warrants, and accompanying warrants for gross proceeds of approximately $90 million, and issues pre-funded warrants to Sermonix for $34.9 million in equity. ($124.85M proceeds)

8-K filing: Stock split 1-for-10 | Outstanding: 39,092,961 → 3,909,296

10-Q filing | 39.1M shares outstanding

10-Q filing | 39.0M shares outstanding

10-K filing | 38.5M shares outstanding

10-Q filing | 38.5M shares outstanding

S-3 filing: Athira Pharma, Inc. is filing an S-3 to offer common stock, preferred stock, debt securities, depositary shares, subscription rights, and purchase contracts for up to $300,000,000.

10-Q filing | 38.4M shares outstanding

10-Q filing | 38.3M shares outstanding

10-K filing | 38.0M shares outstanding

10-Q filing | 38.1M shares outstanding

10-Q filing | 38.0M shares outstanding

10-Q filing | 37.9M shares outstanding

10-K filing | 37.7M shares outstanding

10-Q filing | 37.8M shares outstanding

10-Q filing | 37.8M shares outstanding

10-Q filing | 37.6M shares outstanding

10-K filing | 37.6M shares outstanding

S-3 filing: ATHIRA PHARMA, INC. is filing an S-3 to register an indeterminate amount of common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock, debt securities or depositary shares of the registrant, subscription rights to purchase common stock, preferred stock, debt securities, depositary shares, warrants or units consisting of some or all of these securities of the registrant, purchase contracts, and units consisting of some or all of these securities, as may be sold from time to time by the registrant up to $300,000,000.

10-Q filing | 37.4M shares outstanding

10-Q filing | 37.3M shares outstanding

10-Q filing | 37.2M shares outstanding

10-K filing | 37.1M shares outstanding

S-1 filing: This S-1 filing is for an offering of common stock with a proposed amount of $119,646,000 and an offering of 4,000,000 shares of common stock. The last reported sale price of the common stock on January 15, 2021, was $26.55 per share.

10-Q filing | 32.5M shares outstanding

S-1/A filing: S-1/A filing for convertible preferred stock with 12,646,147 shares authorized and 12,503,009 shares issued and outstanding.

S-1/A filing: Athira Pharma, Inc. is offering 10,000,000 shares of common stock in its initial public offering, with an estimated price range of $15.00 to $17.00 per share, for a total proposed amount of $195,500,000.

S-1/A filing: This S-1/A filing outlines the terms of an underwriting agreement for Athira Pharma, Inc. to issue and sell common stock to underwriters, with Goldman Sachs & Co. LLC and Jefferies LLC as representatives.

S-1 filing: Athira Pharma, Inc. is offering shares of common stock in an initial public offering, with a proposed maximum aggregate offering price of $100,000,000, including additional shares that the underwriters have the option to purchase.